Published in Cancer Immunol Immunother on July 27, 2005
Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol (2008) 9.25
Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest (2007) 6.31
Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell (2012) 5.77
Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med (2007) 5.65
Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J Exp Med (2008) 5.23
Immune surveillance of tumors. J Clin Invest (2007) 5.04
All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res (2006) 4.06
HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med (2010) 4.00
Tregs and rethinking cancer immunotherapy. J Clin Invest (2007) 3.77
Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells. J Immunol (2009) 3.23
Tumor entrained neutrophils inhibit seeding in the premetastatic lung. Cancer Cell (2011) 2.96
Migratory neighbors and distant invaders: tumor-associated niche cells. Genes Dev (2008) 2.95
Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma. J Clin Oncol (2008) 2.77
Immune surveillance: a balance between protumor and antitumor immunity. Curr Opin Genet Dev (2008) 2.62
Retracted FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer. J Clin Invest (2011) 2.44
A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. Clin Cancer Res (2010) 1.89
Immunogenicity of premalignant lesions is the primary cause of general cytotoxic T lymphocyte unresponsiveness. J Exp Med (2008) 1.70
Subsets, expansion and activation of myeloid-derived suppressor cells. Med Microbiol Immunol (2010) 1.67
Tumor immunoediting and immunosculpting pathways to cancer progression. Semin Cancer Biol (2007) 1.55
Cancer immunosuppression and autoimmune disease: beyond immunosuppressive networks for tumour immunity. Immunology (2006) 1.54
Peptide vaccine given with a Toll-like receptor agonist is effective for the treatment and prevention of spontaneous breast tumors. Cancer Res (2007) 1.49
Host A(2B) adenosine receptors promote carcinoma growth. Neoplasia (2008) 1.43
Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated with elevated levels of VEGF. Blood (2007) 1.38
Antibody association with HER-2/neu-targeted vaccine enhances CD8 T cell responses in mice through Fc-mediated activation of DCs. J Clin Invest (2008) 1.28
Myeloid cells in the tumor microenvironment: modulation of tumor angiogenesis and tumor inflammation. J Oncol (2010) 1.28
The Multifaceted Roles Neutrophils Play in the Tumor Microenvironment. Cancer Microenviron (2014) 1.24
Myeloid-derived suppressor cells in transplantation and cancer. Immunol Res (2012) 1.23
The cardioprotective protein apolipoprotein A1 promotes potent anti-tumorigenic effects. J Biol Chem (2013) 1.22
Blockade of myeloid-derived suppressor cells after induction of lymphopenia improves adoptive T cell therapy in a murine model of melanoma. J Immunol (2012) 1.20
Myeloid-derived suppressor cells expand during breast cancer progression and promote tumor-induced bone destruction. Oncoimmunology (2012) 1.19
An oncolytic adenovirus enhanced for toll-like receptor 9 stimulation increases antitumor immune responses and tumor clearance. Mol Ther (2012) 1.18
Inducible cutaneous inflammation reveals a protumorigenic role for keratinocyte CXCR2 in skin carcinogenesis. Cancer Res (2009) 1.17
Effect of granulocyte/macrophage colony-stimulating factor on vaccination with an allogeneic whole-cell melanoma vaccine. Clin Cancer Res (2009) 1.17
Induction of myelodysplasia by myeloid-derived suppressor cells. J Clin Invest (2013) 1.15
Bone marrow and the control of immunity. Cell Mol Immunol (2011) 1.15
Increased frequency and clinical significance of myeloid-derived suppressor cells in human colorectal carcinoma. World J Gastroenterol (2012) 1.10
Hyperthermia as an immunotherapy strategy for cancer. Curr Opin Investig Drugs (2009) 1.09
The role of interleukin-12 on modulating myeloid-derived suppressor cells, increasing overall survival and reducing metastasis. Immunology (2011) 1.08
Curcumin reverses breast tumor exosomes mediated immune suppression of NK cell tumor cytotoxicity. Biochim Biophys Acta (2007) 1.05
Activation of MDL-1 (CLEC5A) on immature myeloid cells triggers lethal shock in mice. J Clin Invest (2011) 1.01
Myeloid-derived suppressor cells from tumor-bearing mice impair TGF-β-induced differentiation of CD4+CD25+FoxP3+ Tregs from CD4+CD25-FoxP3- T cells. J Leukoc Biol (2012) 1.00
Pancreatic tumors and immature immunosuppressive myeloid cells in blood and spleen: role of inhibitory co-stimulatory molecules PDL1 and CTLA4. An in vivo and in vitro study. PLoS One (2013) 1.00
Monocyte-derived DC maturation strategies and related pathways: a transcriptional view. Cancer Immunol Immunother (2011) 0.99
The dendritic cell-regulatory T lymphocyte crosstalk contributes to tumor-induced tolerance. Clin Dev Immunol (2011) 0.99
MicroRNA-155 deficiency enhances the recruitment and functions of myeloid-derived suppressor cells in tumor microenvironment and promotes solid tumor growth. Int J Cancer (2014) 0.99
Cancer prevention and therapy through the modulation of the tumor microenvironment. Semin Cancer Biol (2015) 0.97
Ways to enhance lymphocyte trafficking into tumors and fitness of tumor infiltrating lymphocytes. Front Oncol (2013) 0.95
A PK2/Bv8/PROK2 antagonist suppresses tumorigenic processes by inhibiting angiogenesis in glioma and blocking myeloid cell infiltration in pancreatic cancer. PLoS One (2013) 0.95
Interferon regulatory factor-8 modulates the development of tumour-induced CD11b+Gr-1+ myeloid cells. J Cell Mol Med (2009) 0.94
JAK-STAT pathway in carcinogenesis: is it relevant to cholangiocarcinoma progression? World J Gastroenterol (2007) 0.90
Adenosine as an endogenous immunoregulator in cancer pathogenesis: where to go? Purinergic Signal (2012) 0.88
Radiation as immunomodulator: implications for dendritic cell-based immunotherapy. Radiat Res (2014) 0.87
Targeted STAT3 disruption in myeloid cells alters immunosuppressor cell abundance in a murine model of spontaneous medulloblastoma. J Leukoc Biol (2013) 0.86
TLR8 signaling enhances tumor immunity by preventing tumor-induced T-cell senescence. EMBO Mol Med (2014) 0.86
Strategies to use immune modulators in therapeutic vaccines against cancer. Semin Oncol (2012) 0.86
Tumor microenvironment profoundly modifies functional status of macrophages: peritoneal and tumor-associated macrophages are two very different subpopulations. Cell Immunol (2013) 0.84
Anti-angiogenesis immunotherapy. Hum Vaccin (2011) 0.83
Molecular mechanisms of liver metastasis. Int J Clin Oncol (2011) 0.83
Surveillance on the status of immune cells after Echinnococcus granulosus protoscoleces infection in Balb/c mice. PLoS One (2013) 0.83
CpG-mediated modulation of MDSC contributes to the efficacy of Ad5-TRAIL therapy against renal cell carcinoma. Cancer Immunol Immunother (2014) 0.82
CD33⁺/p-STAT1⁺ double-positive cell as a prognostic factor for stage IIIa gastric cancer. Med Oncol (2013) 0.82
Histone deacetylase 11: A novel epigenetic regulator of myeloid derived suppressor cell expansion and function. Mol Immunol (2014) 0.81
Tumor growth decreases NK and B cells as well as common lymphoid progenitor. PLoS One (2008) 0.81
Lipid A-mediated tolerance and cancer therapy. Adv Exp Med Biol (2010) 0.80
Immune regulation of bone metastasis. Bonekey Rep (2014) 0.80
Cycloamylose-nanogel drug delivery system-mediated intratumor silencing of the vascular endothelial growth factor regulates neovascularization in tumor microenvironment. Cancer Sci (2014) 0.80
New roads open up for implementing immunotherapy in mesothelioma. Clin Dev Immunol (2012) 0.80
Impaired CXCL4 expression in tumor-associated macrophages (TAMs) of ovarian cancers arising in endometriosis. Cancer Biol Ther (2012) 0.79
CpG expedites regression of local and systemic tumors when combined with activatable nanodelivery. J Control Release (2015) 0.79
Mononuclear phagocytes in head and neck squamous cell carcinoma. Eur Arch Otorhinolaryngol (2009) 0.79
Autoantibodies as biomarkers for ovarian cancer. Cancer Biomark (2011) 0.79
Dopamine inhibits the function of Gr-1+CD115+ myeloid-derived suppressor cells through D1-like receptors and enhances anti-tumor immunity. J Leukoc Biol (2014) 0.78
Challenges and future perspectives of T cell immunotherapy in cancer. Immunol Lett (2015) 0.78
Therapeutic vaccines for malignant brain tumors. Biologics (2008) 0.78
Myeloid-derived suppressor cells in cancer cachexia syndrome: a new explanation for an old problem. JPEN J Parenter Enteral Nutr (2008) 0.78
Expansion of myeloid derived suppressor cells correlates with number of T regulatory cells and disease progression in myelodysplastic syndrome. Oncoimmunology (2015) 0.77
Lipid A-mediated tolerance and cancer therapy. Adv Exp Med Biol (2009) 0.77
Lineage -CD34+CD31+ cells that appear in association with severe burn injury are inhibitory on the production of antimicrobial peptides by epidermal keratinocytes. PLoS One (2014) 0.77
Usage of cancer associated autoantibodies in the detection of disease. Cancer Biomark (2010) 0.76
Immunotherapy for lung cancers. J Biomed Biotechnol (2011) 0.76
Isolation of myeloid-derived suppressor cells subsets from spleens of orthotopic liver cancer-bearing mice by fluorescent-activated and magnetic-activated cell sorting: similarities and differences. Int J Clin Exp Pathol (2014) 0.76
The cholesterol-binding protein NPC2 restrains recruitment of stromal macrophage-lineage cells to early-stage lung tumours. EMBO Mol Med (2015) 0.75
Stress and Non-Stress Roles of Inflammatory Signals during HSC Emergence and Maintenance. Front Immunol (2016) 0.75
Myeloid-derived suppressor cells mediate tolerance induction in autoimmune disease. Immunology (2017) 0.75
Investigating the Role of Surface Materials and Three Dimensional Architecture on In Vitro Differentiation of Porcine Monocyte-Derived Dendritic Cells. PLoS One (2016) 0.75
Natural killer cells require monocytic Gr-1(+)/CD11b(+) myeloid cells to eradicate orthotopically engrafted glioma cells. Oncoimmunology (2016) 0.75
Protection by LPS-induced inhibitory CD11b(+) cells on corneal allograft. Int J Clin Exp Med (2015) 0.75
Potential Therapeutic Use of PPARgamma-Programed Human Monocyte-Derived Dendritic Cells in Cancer Vaccination Therapy. PPAR Res (2008) 0.75
Paradoxical myeloid-derived suppressor cell reduction in the bone marrow of SIV chronically infected macaques. PLoS Pathog (2017) 0.75
Stat6 Promotes Intestinal Tumorigenesis in a Mouse Model of Adenomatous Polyposis by Expansion of MDSCs and Inhibition of Cytotoxic CD8 Response. Neoplasia (2017) 0.75
Recruitment of CD11b(+)Ly6C(+) monocytes in non-small cell lung cancer xenografts challenged by anti-VEGF antibody. Oncol Lett (2017) 0.75
Effects of Shugan Jianpi Formula () on myeloid-derived suppression cells-mediated depression breast cancer mice. Chin J Integr Med (2016) 0.75
Novel therapeutic approach to improve hematopoiesis in low risk MDS by targeting MDSCs with the Fc-engineered CD33 antibody BI 836858. Leukemia (2017) 0.75
l-Arginine Uptake by Cationic Amino Acid Transporter Promotes Intra-Macrophage Survival of Leishmania donovani by Enhancing Arginase-Mediated Polyamine Synthesis. Front Immunol (2017) 0.75
Inflammation and cancer: back to Virchow? Lancet (2001) 27.40
Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol (2002) 17.85
Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer (2004) 14.55
IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature (2001) 11.03
Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell (2004) 7.61
Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol (2001) 7.43
Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res (2005) 6.66
Arginine metabolism: nitric oxide and beyond. Biochem J (1998) 6.44
Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med (2003) 5.96
Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol (2004) 5.78
Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J Immunol (2004) 5.73
Characterization and regulation of RB6-8C5 antigen expression on murine bone marrow cells. J Immunol (1991) 5.02
Stat proteins and oncogenesis. J Clin Invest (2002) 4.79
Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells. Blood (2000) 4.78
Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res (2004) 4.74
Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. Cancer Res (2001) 4.49
Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J Immunol (2005) 4.47
Nuclear factor kappa B: an oxidative stress-responsive transcription factor of eukaryotic cells (a review). Free Radic Res Commun (1992) 4.45
Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells. J Immunol (2001) 3.81
IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice. J Immunol (2003) 3.69
Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. Blood (2003) 3.47
Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res (2000) 3.47
All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res (2003) 3.45
STAT1 signaling regulates tumor-associated macrophage-mediated T cell deletion. J Immunol (2005) 3.32
Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer. J Immunol (2004) 3.24
Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers. J Exp Med (2005) 3.13
Gr-1+ myeloid cells derived from tumor-bearing mice inhibit primary T cell activation induced through CD3/CD28 costimulation. J Immunol (2000) 3.07
Reactive oxygen species as intracellular messengers during cell growth and differentiation. Cell Physiol Biochem (2001) 3.07
Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells. J Immunol (1998) 3.03
Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation. J Immunol (1999) 2.94
Inhibition of myeloid cell differentiation in cancer: the role of reactive oxygen species. J Leukoc Biol (2003) 2.94
L-arginine consumption by macrophages modulates the expression of CD3 zeta chain in T lymphocytes. J Immunol (2003) 2.91
Regulation of T cell receptor CD3zeta chain expression by L-arginine. J Biol Chem (2002) 2.62
Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination. Proc Natl Acad Sci U S A (2005) 2.49
A critical role for Stat3 signaling in immune tolerance. Immunity (2003) 2.41
Vitamin A deficiency in mice causes a systemic expansion of myeloid cells. Blood (2000) 2.30
Tumor-induced immune dysfunctions caused by myeloid suppressor cells. J Immunother (2001) 2.25
Synergy between T-cell immunity and inhibition of paracrine stimulation causes tumor rejection. Proc Natl Acad Sci U S A (1995) 1.94
Role of immature myeloid Gr-1+ cells in the development of antitumor immunity. Cancer Res (2004) 1.85
Myeloid progenitor cells mediate immune suppression in patients with head and neck cancers. Int J Immunopharmacol (1999) 1.82
Oxidative stress by tumor-derived macrophages suppresses the expression of CD3 zeta chain of T-cell receptor complex and antigen-specific T-cell responses. Proc Natl Acad Sci U S A (1996) 1.79
A schistosome-expressed immunomodulatory glycoconjugate expands peritoneal Gr1(+) macrophages that suppress naive CD4(+) T cell proliferation via an IFN-gamma and nitric oxide-dependent mechanism. J Immunol (2001) 1.78
Suppression of T cell proliferation by tumor-induced granulocyte-macrophage progenitor cells producing transforming growth factor-beta and nitric oxide. J Immunol (1996) 1.75
CD80+Gr-1+ myeloid cells inhibit development of antifungal Th1 immunity in mice with candidiasis. J Immunol (2002) 1.73
Resistance to metastatic disease in STAT6-deficient mice requires hemopoietic and nonhemopoietic cells and is IFN-gamma dependent. J Immunol (2002) 1.66
CD34+ immune suppressive cells in the peripheral blood of patients with head and neck cancer. Ann Otol Rhinol Laryngol (2000) 1.57
Nitric oxide biosynthesis, nitric oxide synthase inhibitors and arginase competition for L-arginine utilization. Cell Mol Life Sci (1999) 1.54
Phase 1B study to improve immune responses in head and neck cancer patients using escalating doses of 25-hydroxyvitamin D3. Cancer Immunol Immunother (2003) 1.41
Retinoic acid receptor antagonism in vivo expands the numbers of precursor cells during granulopoiesis. Leukemia (2002) 1.36
Tumor-infiltrating macrophages induce apoptosis in activated CD8(+) T cells by a mechanism requiring cell contact and mediated by both the cell-associated form of TNF and nitric oxide. J Immunol (2001) 1.35
Cyclophosphamide induces the development of early myeloid cells suppressing tumor cell growth by a nitric oxide-dependent mechanism. J Immunol (2001) 1.31
Resection of solid tumors reverses T cell defects and restores protective immunity. J Immunol (2000) 1.29
Superantigen-induced CD4 T cell tolerance mediated by myeloid cells and IFN-gamma. J Immunol (2000) 1.28
Nitric oxide-independent CTL suppression during tumor progression: association with arginase-producing (M2) myeloid cells. J Immunol (2003) 1.23
Physiological concentrations of retinoic acid favor myeloid dendritic cell development over granulocyte development in cultures of bone marrow cells from mice. J Nutr (2004) 1.23
IL-4 prevents the blockade of dendritic cell differentiation induced by tumor cells. Cancer Res (2001) 1.05
Development of splenic natural suppressor (NS) cells in Ehrlich tumor-bearing mice. Int J Cancer (1989) 1.03
C-kit+ FcR+ myelocytes are increased in cancer and prevent the proliferation of fully cytolytic T cells in the presence of immune serum. Eur J Immunol (2003) 1.01
H1(0) histone and differentiation of dendritic cells. A molecular target for tumor-derived factors. J Leukoc Biol (2002) 0.99
Treating tumor-bearing mice with vitamin D3 diminishes tumor-induced myelopoiesis and associated immunosuppression, and reduces tumor metastasis and recurrence. Cancer Immunol Immunother (1995) 0.89
Vitamin D3 treatment to diminish the levels of immune suppressive CD34+ cells increases the effectiveness of adoptive immunotherapy. J Immunother (2000) 0.88
Tumor skewing of CD34+ progenitor cell differentiation into endothelial cells. Int J Cancer (2004) 0.86
Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol (2008) 9.25
Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J Immunol (2004) 5.73
Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med (2007) 5.65
MyD88-dependent expansion of an immature GR-1(+)CD11b(+) population induces T cell suppression and Th2 polarization in sepsis. J Exp Med (2007) 5.48
Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J Exp Med (2008) 5.23
The terminology issue for myeloid-derived suppressor cells. Cancer Res (2007) 4.37
All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res (2006) 4.06
HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med (2010) 4.00
Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. J Clin Invest (2010) 3.97
Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. Trends Immunol (2010) 3.86
STAT1 signaling regulates tumor-associated macrophage-mediated T cell deletion. J Immunol (2005) 3.32
Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells. J Immunol (2009) 3.23
Tumor-associated CD8+ T cell tolerance induced by bone marrow-derived immature myeloid cells. J Immunol (2005) 3.20
History of myeloid-derived suppressor cells. Nat Rev Cancer (2013) 3.14
The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity. Eur J Immunol (2010) 2.94
Inhibition of myeloid cell differentiation in cancer: the role of reactive oxygen species. J Leukoc Biol (2003) 2.94
Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res (2006) 2.68
Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother (2002) 2.65
Immature myeloid cells and cancer-associated immune suppression. Cancer Immunol Immunother (2002) 2.60
Tumor escape mechanism governed by myeloid-derived suppressor cells. Cancer Res (2008) 2.56
Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines. Blood (2003) 2.41
Myeloid-derived suppressor cells in human cancer. Cancer J (2010) 2.36
Vascular endothelial growth factor-trap overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responses. Clin Cancer Res (2007) 2.28
Lipid accumulation and dendritic cell dysfunction in cancer. Nat Med (2010) 2.21
Mechanism of T cell tolerance induced by myeloid-derived suppressor cells. J Immunol (2010) 2.20
Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer. Clin Cancer Res (2010) 2.19
Characterization of the nature of granulocytic myeloid-derived suppressor cells in tumor-bearing mice. J Leukoc Biol (2011) 2.06
Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells. Cancer Res (2007) 2.06
Full-length dominant-negative survivin for cancer immunotherapy. Clin Cancer Res (2003) 2.00
VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. Blood (2003) 1.99
Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. J Clin Invest (2015) 1.92
Epigenetic silencing of retinoblastoma gene regulates pathologic differentiation of myeloid cells in cancer. Nat Immunol (2013) 1.81
Rational design of shepherdin, a novel anticancer agent. Cancer Cell (2005) 1.74
Inhibition of Notch signaling induces apoptosis of myeloma cells and enhances sensitivity to chemotherapy. Blood (2007) 1.65
Activation of dendritic cells via inhibition of Jak2/STAT3 signaling. J Immunol (2005) 1.61
Myeloid-derived suppressor cells. Adv Exp Med Biol (2007) 1.55
Notch and wingless signaling cooperate in regulation of dendritic cell differentiation. Immunity (2009) 1.37
Molecular mechanisms and therapeutic reversal of immune suppression in cancer. Curr Cancer Drug Targets (2007) 1.37
Reciprocal relationship between myeloid-derived suppressor cells and T cells. J Immunol (2013) 1.34
Effect of tumor-derived cytokines and growth factors on differentiation and immune suppressive features of myeloid cells in cancer. Cancer Metastasis Rev (2006) 1.32
Regulation of tumor metastasis by myeloid-derived suppressor cells. Annu Rev Med (2014) 1.29
Dendritic cells and tumor microenvironment: a dangerous liaison. Immunol Invest (2006) 1.26
Regulation of dendritic-cell differentiation by bone marrow stroma via different Notch ligands. Blood (2006) 1.25
Combination of external beam radiotherapy (EBRT) with intratumoral injection of dendritic cells as neo-adjuvant treatment of high-risk soft tissue sarcoma patients. Int J Radiat Oncol Biol Phys (2011) 1.17
ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R-mediated apoptosis. J Clin Invest (2014) 1.16
Induction of myelodysplasia by myeloid-derived suppressor cells. J Clin Invest (2013) 1.15
Dendritic cell-based full-length survivin vaccine in treatment of experimental tumors. J Immunother (2007) 1.13
INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect. Expert Opin Biol Ther (2010) 1.12
Hypoxia-inducible factors in regulation of immune responses in tumour microenvironment. Immunology (2014) 1.10
Antigen-specific CD4(+) T cells regulate function of myeloid-derived suppressor cells in cancer via retrograde MHC class II signaling. Cancer Res (2012) 1.10
Mechanism and therapeutic reversal of immune suppression in cancer. Cancer Res (2007) 1.08
Regulatory myeloid suppressor cells in health and disease. Cancer Res (2009) 1.07
Novel mechanism of synergistic effects of conventional chemotherapy and immune therapy of cancer. Cancer Immunol Immunother (2013) 1.07
Combined modality immunotherapy and chemotherapy: a new perspective. Cancer Immunol Immunother (2008) 1.04
Myeloid-derived suppressor cells in the development of lung cancer. Cancer Immunol Res (2013) 1.02
Molecular pathways: tumor-infiltrating myeloid cells and reactive oxygen species in regulation of tumor microenvironment. Clin Cancer Res (2012) 1.01
Targeting of Jak/STAT pathway in antigen presenting cells in cancer. Curr Cancer Drug Targets (2007) 1.00
Regulation of suppressive function of myeloid-derived suppressor cells by CD4+ T cells. Semin Cancer Biol (2012) 0.95
Tumor-induced STAT3 signaling in myeloid cells impairs dendritic cell generation by decreasing PKCβII abundance. Sci Signal (2014) 0.95
Combined inhibition of Notch signaling and Bcl-2/Bcl-xL results in synergistic antimyeloma effect. Mol Cancer Ther (2010) 0.93
Mechanism of synergistic effect of chemotherapy and immunotherapy of cancer. Cancer Immunol Immunother (2010) 0.91
Autophagy induced by conventional chemotherapy mediates tumor cell sensitivity to immunotherapy. Cancer Res (2012) 0.90
Oxidized lipids block antigen cross-presentation by dendritic cells in cancer. J Immunol (2014) 0.89
Developing dendritic cells become 'lacy' cells packed with fat and glycogen. Immunology (2005) 0.88
Regulation of dendritic cell differentiation in bone marrow during emergency myelopoiesis. J Immunol (2013) 0.85
Radiation-induced autophagy potentiates immunotherapy of cancer via up-regulation of mannose 6-phosphate receptor on tumor cells in mice. Cancer Immunol Immunother (2014) 0.83
The role of mannose-6-phosphate receptor and autophagy in influencing the outcome of combination therapy. Autophagy (2013) 0.78
Mass-spectrometric characterization of peroxidized and hydrolyzed lipids in plasma and dendritic cells of tumor-bearing animals. Biochem Biophys Res Commun (2011) 0.78
Therapeutic effect of intratumoral administration of DCs with conditional expression of combination of different cytokines. Cancer Immunol Immunother (2012) 0.78
New roles of Rb1 in expansion of MDSCs in cancer. Cell Cycle (2013) 0.77